About Amzell - Making Good drugs work better

Who we are and what we do

Amzell BV is a specialist, virtual development pharmaceutical company which takes candidate or re purposed drugs and devices either through to proof of concept, or through to registration for sale to commercial healthcare companies.

The company, which is based in Hoofddorp in the Netherlands, was founded in 2016 and is part of the Frederik Paulsen business interests which consists of a number of healthcare companies including Ferring Pharmaceuticals.

Amzell BV has a particular interest in developing well-characterized active substances utilizing innovative platform drug delivery technologies, which provide more effective drug delivery, increased efficacy, and improved safety and compliance.

Our mission is to make good drugs work better.


Amzell has a highly experienced drug and device development team which has extensive expertise in optimising development pathways to create products which will offer the best commercial opportunities.

This core team analyses each program so that they have a thorough understanding of the biology, mode of action, and the development path to provide the optimal delivery solution. Working with best-in-class partners from across the world enables Amzell to pull together a bespoke, expert team tailored for each program.

AMZELL is an expert in in-licencing drug development programs and taking them through from proof of concept to marketing authorisation in key markets. Amzell does this by developing bespoke scientific solutions which deliver patent-protected drugs across multiple therapeutic areas based on Amzell’s platform technologies.

Through its interdisciplinary expertise and working with best-in-class partners from across the world Amzell provides answers to complex problems. This is coupled with a holistic approach to CMC and innovative drug delivery solutions.

Where a combination product is being developed the design and safety issues of the device is carried out in parallel from an early stage so as to move forward with better control of the development pathway.

AMZELL has expertise in re positioning complicated formulations while making use of the 505(b)(2) regulatory pathway for new drug approvals.

Its success is based on a core team with wide-ranging experience in development research, processes, clinical programs, QA/QC and regulatory affairs, intellectual property and its ability to partner effectively with a global network of specialist experts.

Our Vision

To become the leading research company specialising in the repurposing of existing drugs and devices which brings new effective solutions to patients.